Data-integrated modeling to provide novel solutions for individualizing cancer therapy and predicting treatment success

PN 2-1 A

Project description

We will develop novel data-integrated solutions to address the gap between the molecular understanding of network-coded death decisions in cancer cells and their higher scale consequences on patient outcome. For this, we will build on preparatory work in which we demonstrated that prototype mathematical models of cell death commitment at the level of the Bcl-2 protein family and at the level of multi-protein apoptosome timers hold potential to predict the responses of cancer cells to established and novel therapeutics, and possibly to predict clinical patient outcome. Linked with the systems-theoretical and technological challenges addressed in PN 2-1B, we will thereby obtain novel, translationally relevant systems medicine tools for the prediction of treatment success in heterogeneous cancers.

Project information

Project title Data-integrated modeling to provide novel solutions for individualizing cancer therapy and predicting treatment success
Project leaders Markus Morrison (Nicole Radde)
Project duration July 2019 - December 2022
Project number PN 2-1 A

Publications PN 2-1 A and PN 2-1 (II)

  1. 2023

    1. C. Guttà, C. Morhard, and M. Rehm, “Applying a GAN-based classifier to improve transcriptome-based prognostication in breast cancer,” PLOS Computational Biology, vol. 19, no. 4, Art. no. 4, Apr. 2023, doi: 10.1371/journal.pcbi.1011035.
  2. 2022

    1. J. Vera et al., “Melanoma 2.0. Skin cancer as a paradigm for emerging diagnostic technologies, computational modelling and artificial intelligence,” Briefings in Bioinformatics, Oct. 2022, doi: 10.1093/BIB/BBAC433.
  3. 2020

    1. G. Fullstone, T. L. Bauer, C. Guttà, M. Salvucci, J. H. M. Prehn, and M. Rehm, “The apoptosome molecular timer synergises with XIAP to suppress apoptosis execution and contributes to prognosticating survival in colorectal cancer,” Cell Death & Differentiation, no. 27, Art. no. 27, 2020, doi: 10.1038/s41418-020-0545-9.
    2. V. Vetma et al., “Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism,” Cell Death & Differentiation, vol. 27, no. 8, Art. no. 8, Feb. 2020, doi: 10.1038/s41418-020-0512-5.
To the top of the page